Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ketamine + midazolam
- Development stage
- Phase 4
- Lead developer
- Harrow
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
ketamine + midazolam is a combination therapy being evaluated by Inonu University for its efficacy in reducing postpartum depression and managing postoperative pain in patients undergoing Cesarean section under spinal anesthesia. Ketamine acts as a non-competitive NMDA receptor antagonist, providing rapid antidepressant and analgesic effects. Midazolam, a short-acting benzodiazepine, acts as a positive allosteric modulator of the GABA-A receptor and is included in the regimen to provide sedation and mitigate potential psychomimetic side effects associated with ketamine, such as hallucinations and delirium.
- Other names
- ketamine and midazolam
02
Targets
GABRR (GABA-A receptor subunit rho)GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on ketamine + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ketamine + midazolam.